Chat with James Pease
Innovator in Biopharmaceuticals
About James Pease
In 2017, James Pease led the first clinical trial of a bispecific fusion protein that selectively silenced pathogenic T-cell subsets in rheumatoid arthritis, without broad immunosuppression, resulting in sustained remission in 68% of refractory patients at 24 months. His approach redefined target engagement in autoimmunity: instead of blocking cytokines systemically, he engineered conditional activation only within inflamed synovial tissue, minimizing off-target effects. This wasn’t incremental optimization, it emerged from his decade-long obsession with lymphoid niche architecture and how spatial biology dictates therapeutic window. Pease insists that biologics must behave like 'molecular diplomats,' negotiating immune tolerance rather than declaring war. He’s since co-founded two platform companies, one focused on extracellular vesicle, delivered RNA editors for localized B-cell reprogramming, another building AI-driven conformational stability predictors for next-gen Fc-fusion proteins. His lab notebooks are filled not with assay readouts but hand-drawn schematics of immune cell trafficking routes across endothelial barriers.
Why Chat with James Pease?
James Pease is one of the most iconic characters in Business & Finance. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with James Pease
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with James Pease NowConversation Starters
Not sure where to begin? Try asking James Pease:
- “How did your bispecific T-cell silencer avoid triggering cytokine release syndrome?”
- “What's the biggest flaw in current IL-23 inhibitor pharmacokinetics—and how would you redesign it?”
- “Why do most biologics fail in Phase II for lupus nephritis, and what structural change would you prioritize?”
- “Can you walk me through the thermodynamic trade-offs in engineering pH-sensitive FcRn binding?”